towards improved death receptor targeted therapy for ... - TI Pharma

Chapter 4
variants. Cell Death Dis 2010; 1:e83.
22. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A et al. Designed tumor
necrosis factor‐related apoptosis‐inducing ligand variants initiating apoptosis exclusively
via the DR5 receptor. Proc Natl Acad Sci U S A 2006; 103(23):8634‐8639.
23. Voortman J, Resende TP, bou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non‐
small cell lung cancer cells: sensitization to death receptor‐mediated apoptosis by
proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6(7):2103‐2112.
24. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between
life and death. Int J Biochem Cell Biol 2007; 39(7‐8):1462‐1475.
25. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS‐354825) tyrosine kinase
inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck
squamous cell carcinoma and non‐small cell lung cancer cells. Clin Cancer Res 2005; 11(19
Pt 1):6924‐6932.
26. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH et al. The Src inhibitor
AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac
Oncol 2009; 4(4):448‐454.
27. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL
and TRAIL death receptors in stage III non‐small cell lung cancer tumors. Clin Cancer Res
2003; 9(9):3397‐3405.
28. Gallick GE. SRC as a potential therapeutic target in solid tumor oncology. Clin Adv Hematol
Oncol 2004; 2(7):435‐437.
29. Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL. Expression of pp60c‐src in human
small cell and non‐small cell lung carcinomas. Eur J Cancer 1992; 28(2‐3):372‐377.
30. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223(1):14‐26.
31. Mukhopadhyay UK, Mooney P, Jia L, Eves R, Raptis L, Mak AS. Doubles game: Src‐Stat3
versus p53‐PTEN in cellular migration and invasion. Mol Cell Biol 2010; 30(21):4980‐4995.
32. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G et al. Stat3 promotes
metastatic progression of prostate cancer. Am J Pathol 2008; 172(6):1717‐1728.
33. Teng TS, Lin B, Manser E, Ng DC, Cao X. Stat3 promotes directional cell migration by
regulating Rac1 activity via its activator betaPIX. J Cell Sci 2009; 122(Pt 22):4150‐4159.
34. Snyder M, Huang XY, Zhang JJ. Signal transducers and activators of transcription 3 (STAT3)
directly regulates cytokine‐induced fascin expression and is required for breast cancer cell
migration. J Biol Chem 2011; 286(45):38886‐38893.
35. Boyer B, Bourgeois Y, Poupon MF. Src kinase contributes to the metastatic spread of
carcinoma cells. Oncogene 2002; 21(15):2347‐2356.
36. Kalluri R, Weinberg RA. The basics of epithelial‐mesenchymal transition. J Clin Invest 2009;
119(6):1420‐1428.
37. van Nimwegen MJ, van de WB. Focal adhesion kinase: a potential target in cancer therapy.
Biochem Pharmacol 2007; 73(5):597‐609.
38. Cursi S, Rufini A, Stagni V, Condo I, Matafora V, Bachi A et al. Src kinase phosphorylates
Caspase‐8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J 2006;
25(9):1895‐1905.
39. Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in
apoptosis‐resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006;
290(1):G129‐G136.
40. Song JH, Tse MC, Bellail A, Phuphanich S, Khuri F, Kneteman NM et al. Lipid rafts and
nonrafts mediate tumor necrosis factor related apoptosis‐inducing ligand induced
apoptotic and non‐apoptotic signals in non small cell lung carcinoma cells. Cancer Res
2007; 67(14):6946‐6955.
41. Song JJ, Kim JH, Sun BK, Alcala MA, Jr., Bartlett DL, Lee YJ. c‐Cbl acts as a mediator of Src‐
induced activation of the PI3K‐Akt signal transduction pathway during TRAIL treatment.
‐ 80 ‐